ERAS Latest Headlines

Analysts Conflicted on These Healthcare Names: Erasca (ERAS) and Mereo Biopharma Group Plc (MREO)

at www.tipranks.com (Thu, 26-Mar 8:21 AM)

Erasca’s HERKULES-3 Trial Reaches Completion: What Investors Should Watch in ERAS-007

at www.tipranks.com (Wed, 25-Mar 12:30 PM)

Bank of America Securities Reaffirms Their Sell Rating on Erasca (ERAS)

at www.tipranks.com (Tue, 24-Mar 6:18 AM)

Top performing mid-cap stocks YTD as volatility hits markets

at seekingalpha.com (Mon, 23-Mar 2:47 PM)

Erasca Completes $258.8 Million Upsized Public Offering—Strategic Move Bolsters Pipeline Funding

Market Chameleon (Mon, 26-Jan 7:06 AM)

Erasca to Launch $150 Million Public Offering to Fuel Oncology Research—What’s Next for the Company’s Growth Plans?

Market Chameleon (Wed, 21-Jan 8:20 AM)

Erasca’s Early Clinical Progress Signals Potential Breakthroughs in RAS-Targeting Cancer Therapies

Market Chameleon (Mon, 12-Jan 8:51 AM)

Erasca to Spotlight Oncology Pipeline at J.P. Morgan Healthcare Conference—Investor Attention Turns to RAS/MAPK Strategy

Market Chameleon (Wed, 7-Jan 10:30 AM)

Erasca to Spotlight RAS/MAPK Cancer Therapies at 44th Annual J.P. Morgan Healthcare Conference

Market Chameleon (Tue, 6-Jan 11:10 AM)